Other operating income and expense

6 Months Ended

Jun. 30, 2023

Other operating income and expense

Other operating income and expense

Table 31: Other operating income and expense

	H1 2023	H1 2022
	$m	$m
brazikumab licence termination funding	75	69
Divestment of rights to Plendil	-	61
Divestment of US rights to Pulmicort Flexhaler	241	-
Update to the contractual relationships for Beyfortus (nirsevimab)	712	-
Other	135	89
Total	1,163	219